Staff

1. Chiò Adriano (Coordinator)
2. Calvo Andrea (Member)
3. Moglia Cristina (Member)
4. Cammarosano Stefania (Member)
5. Ilardi Antonio (Member)
6. Canosa Antonio (Member)
7. Manera Umberto (Member)
8. Bertuzzo Davide (Member)
9. (Member)
10. Iazzolino Barbara (Member)
11. Pasian Valentina (Member)
12. Brunetti Maura (Member)
13. Casale Federico (Member)
14. Fuda Giuseppe (Member)
15. (Member)
16. Salamone Paolina (Member)

Contacts

• Send email to members

Activity

Expert Regional Center for ALS (CRESLA) of Turin is  Regional Reference Center for ALS in Piemonte and Valle d'Aosta (DGR 30th December 2009, no. 27-12969). Its research activities are aimed at the study of ALS on the epidemiological, clinical, cognitive, genetic, neuropathological and neurobiological side. The clinical research is in the field of clinical trials, including academics trials, the study of structural and functional neuroimaging markers (MRI and PET), and the study of phenotypic variants (deepphenotyping), with a focus on the cognitive aspects. From the neuroepidemiological point of view CRESLA pertains to the registry of Piedmont and Valle d'Aosta for ALS, recognized as a regional registry of major public health interest (BU 19/04/2012 Piedmont Region, the Regional Law 11 April 2012, n. 4). The registry has been operative since 1995 and it is thelargest registry for ALS worldwide.

The genetic research uses advanced techniques such as GWAS, exomesequencing and genomesequencing and it is aimed at the identification of both causal genes of disease and phenotype regulatory genes (onset age, clinical presentation and disease progression). The CRESLA is consortium center of the genetic national group of ALS (ITALSGEN Consortium) and it has active international cooperation both in Europe and in the United States. The neurobiological research is aimed at identifying in particular proteins and biochemical markers of disease. The methods used provide for the extraction and purification of nucleic acids and proteins and the execution of flow cytometry, Western Blotting, and ELISA techniques. The center also boasts a large biobank of biological material (blood, DNA / RNA, plasma, serum, urine, cells) relative to more than 300 ALS patients and as many healthy controls.

Group’s ECR Sectors:

LS5_11 - Neurological disorders (e.g. Alzheimer's disease, Huntington's disease, Parkinson's disease)

LS5_2 - Molecular and cellular neuroscience

LS2_6 - Molecular genetics, reverse genetics and RNAi

LS7_2 - Diagnostic tools (e.g. genetic, imaging)

Publications

Elamin M, Bede P, Montuschi A, Pender N, Chio A, Hardiman O. (2015) Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. Journal of neurology[DOI  PMID]

Chio A, Mora G, Sabatelli M, Caponnetto C, Traynor BJ, Johnson JO, Nalls MA, Calvo A, Moglia C, Borghero G, Monsurro MR, La Bella V, Volanti P, Simone I, Salvi F, Logullo FO, Nilo R, Battistini S, Mandrioli J, Tanel R, Murru MR, Mandich P, Zollino M, Conforti FL, Brunetti M, Barberis M, Restagno G, Penco S, Lunetta C. (2015) CHCH10 mutations in an Italian cohort of familial and sporadic amyotrophic lateral sclerosis patients. Neurobiology of aging 36(4) 1767.e3-6 [DOI  PMID]

Chio A, Traynor BJ. (2015) Motor neuron disease in 2014. Biomarkers for ALS--in search of the Promised Land. Nature reviews. Neurology 11(2) 72-4 [DOI  PMID]

Chio A, Calvo A, Moglia C, Canosa A, Brunetti M, Barberis M, Restagno G, Conte A, Bisogni G, Marangi G, Moncada A, Lattante S, Zollino M, Sabatelli M, Bagarotti A, Corrado L, Mora G, Bersano E, Mazzini L, D'Alfonso S. (2015) ATXN2 polyQ intermediate repeats are a modifier of ALS survival. Neurology 84(3) 251-8 [DOI  PMID]

Chio A, Pagani M, Agosta F, Calvo A, Cistaro A, Filippi M. (2014) Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. The Lancet. Neurology 13(12) 1228-40 [DOI  PMID]

Canosa A, Calvo A, Barberis M, Brunetti M, Restagno G, Cammarosano S, Ilardi A, Vigliani MC, Chio A, Moglia C. (2015) Amyotrophic lateral sclerosis onset after prolonged treatment with a VEGF receptors inhibitor. Amyotrophic lateral sclerosis & frontotemporal degeneration 16(1-2) 129-30 [DOI  PMID]

Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, Heverin M, Howard RS, Huisman MH, Keren N, Leigh PN, Mazzini L, Mora G, Orrell RW, Rooney J, Scott KM, Scotton WJ, Seelen M, Shaw CE, Sidle KS, Swingler R, Tsuda M, Veldink JH, Visser AE, van den Berg LH, Pearce N. (2014) Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. The Lancet. Neurology 13(11) 1108-13 [DOI  PMID]

Canosa A, Calvo A, Moglia C, Barberis M, Brunetti M, Cammarosano S, Manera U, Ilardi A, Restagno G, Chio A. (2015) A novel p.E121G heterozygous missense mutation of SOD1 in an apparently sporadic ALS case with a 14-year course. Amyotrophic lateral sclerosis & frontotemporal degeneration 16(1-2) 127-8 [DOI  PMID]

Johnson JO, Glynn SM, Gibbs JR, Nalls MA, Sabatelli M, Restagno G, Drory VE, Chio A, Rogaeva E, Traynor BJ. (2014) Mutations in the CHCHD10 gene are a common cause of familial amyotrophic lateral sclerosis. Brain : a journal of neurology 137(Pt 12) e311 [DOI  PMID]

Marrali G, Casale F, Salamone P, Fuda G, Caorsi C, Amoroso A, Brunetti M, Restagno G, Barberis M, Bertuzzo D, Canosa A, Moglia C, Calvo A, Chio A. (2014) NADPH oxidase (NOX2) activity is a modifier of survival in ALS. Journal of neurology 261(11) 2178-83 [DOI  PMID]

Borghero G, Pugliatti M, Marrosu F, Marrosu MG, Murru MR, Floris G, Cannas A, Parish LD, Occhineri P, Cau TB, Loi D, Ticca A, Traccis S, Manera U, Canosa A, Moglia C, Calvo A, Barberis M, Brunetti M, Pliner HA, Renton AE, Nalls MA, Traynor BJ, Restagno G, Chio A. (2014) Genetic architecture of ALS in Sardinia. Neurobiology of aging35(12) 2882.e7-2882.e12 [DOI  PMID]

Pagani M, Chio A, Valentini MC, Oberg J, Nobili F, Calvo A, Moglia C, Bertuzzo D, Morbelli S, De Carli F, Fania P, Cistaro A. (2014) Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology 83(12) 1067-74 [DOI  PMID]

Chio A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, Cugnasco P, Clerico M, De Mercanti S, Bersano E, Cammarosano S, Ilardi A, Manera U, Moglia C, Sideri R, Marinou K, Bottacchi E, Pisano F, Cantello R, Mazzini L, Mora G. (2014) Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA neurology 71(9) 1134-42 [DOI  PMID]